RNA therapeutics promise rapid, personalized and flexible treatments against multiple diseases. In this article, we will ...

From COVID-19 vaccines to rare disease treatments, RNA has become key to tackling many of biotech’s tough obstacles. Stoke ...

SMi’s 11 th annual RNA Therapeutics conference ... where new developments mean that these products are now more stable, and have better translation. At the same time, CRISPR Cas approaches ...

Traditional mRNA-based approaches have shown immense potential, particularly in rapid vaccine deployment and gene replacement therapies. Building upon this foundation, self-amplifying RNA (saRNA) ...

Are you looking to solve challenges with current RNA therapeutics, such as the degradation of RNA by RNAses, the difficulty of RNA crossing the cell membrane by diffusion and the immunogenicity ...

Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that ...

DelveInsight's 'Myotonic Dystrophy Pipeline Insight 2024' report provides comprehensive global coverage of pipeline myotonic ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...

Rznomics, Inc. announced to secure its expanded access program (EAP) from the United States Food and Drug Administration (FDA) for RZ-001, ...

GSA Capital Partners LLP lessened its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) ...

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...